Income StatementBalance SheetCash FlowSegments
Royalty Pharma logo

Royalty Pharma Business Segments

Business, geographic, and product segment breakdowns

Royalty Pharma generates $2.4B in annual revenue across 2 key segments: Income from financial royalty assets ($2.3B), and Other royalty income and revenues ($123.9M). The company-wide operating margin is 65.08%. Based on the Q1 2026 filing.

Income from financial royalty assets (TTM)$2.3BOther royalty income and revenues (TTM)$123.9M
Latest FilingQ1 2026
Report Date2026-05-06
Market Cap$23.1B
P/E Ratio27.90
ROE8.39%

Products & Services

Total income and other revenues

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Income from financial royalty assets$561.8M$539.5M$550.4M$578.8M$592.4M$595.0M
Other royalty income and revenues$31.8M$28.8M$28.2M$30.5M$29.6M$35.6M

Total Commitments

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
JNJ‑4804—————$500.0M
Litifilimab—————$250.0M

Unfunded Commitments

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
JNJ‑4804—————$500.0M
Litifilimab—————$25.0M

Research and development commitment

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Phase 3, TEV-408—————$425.0M
Phase 2b, TEV-408—————$75.0M

Research and development funding expense

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Phase 2b, TEV-408—————$14.3M

Milestone payable

SegmentQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Trelegy$12.5M$12.5M$12.5M$12.5M$12.5M—